New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
19:19 EDTLLYEli Lilly, BIPI announce results of two Phase lll clinical trials
Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults with type 2 diabetes, T2D, Boehringer Ingelheim Pharmaceuticals, BIPI, and Eli Lilly and Company announced. The findings were presented as late breaking abstracts at the American Diabetes Association 74th Scientific Sessions. The 24-week primary findings of these two 52-week trials compared the combination of empagliflozin and linagliptin with empagliflozin or linagliptin alone in patients with T2D and moderately elevated blood glucose levels consistent with what is often seen in clinical practice.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 1, 2016
06:18 EDTLLYTransition Therapeutics announces results from Phase 2 clinical study of TT401
Subscribe for More Information
06:11 EDTLLYTransition Therapeutics reports results from Phase 2 clinical study of TT401
Subscribe for More Information
January 29, 2016
05:20 EDTLLYEli Lilly, Adocia initiate Phase 1b study of BioChaperone Lispro U100
Adocia and Eli Lilly announced the initiation of a Phase 1b clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocia's proprietary technology, BioChaperone, which is designed to enable the acceleration of insulin absorption. The study, under the Adocia-Lilly partnership, aims to compare the pharmacokinetic and pharmacodynamic profiles of BioChaperone Lispro to that of Humalog in 15 healthy Japanese subjects placed under euglycemic clamp.
January 28, 2016
09:55 EDTLLYEli Lilly nears test of key support at $80 area
Subscribe for More Information
06:29 EDTLLYEli Lilly backs FY16 adjusted EPS view of $3.45-$3.55, consensus $3.54
Backs FY16 revenue guidance of $20.2B-$20.7B, consensus $20.83B.
06:27 EDTLLYEli Lilly reports Q4 EPS 78c, consensus 78c
Reports Q4 revenue $5.38B, consensus $5.32B.
January 27, 2016
14:44 EDTLLYEli Lilly volatility elevated into Q4 and outlook
Eli Lilly January weekly call option implied volatility is at 54, February is at 29; compared to its 52-week range of 15 to 41, suggesting large near term price movement into the expected release of Q4 results on January 28.
14:34 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
09:02 EDTLLYEli Lilly and Roche to collaborate on Alzheimer's diagnostic tool
Subscribe for More Information
January 25, 2016
08:36 EDTLLYFDA accepts supplemental NDA for Eli Lilly and Boehringer's Jardiance
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use